Literature DB >> 1596289

Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.

W H Ward1, R Kimbell, A L Jackman.   

Abstract

The thymidylate synthase (TS) inhibitor ICI D1694 (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N -methylamino]-2 - thenoyl)-S-glutamic acid) is a structural analogue of the substrate N5,N10-methylenetetrahydrofolate (5,10-CH2FH4) and is currently under clinical evaluation as a treatment for cancer. The compound is shown here to be a mixed non-competitive inhibitor of TS from murine leukemia (L1210) cells when 5,10-CH2FH4 is varied. This result suggests formation of an inactive complex between TS, 5,10-CH2FH4 and the inhibitor. Thus, binding to only one of the two active sites on the TS homodimer may be sufficient to prevent catalysis fully. Treatment of L1210 cells with ICI D1694 is known to cause intracellular accumulation of the tetraglutamate derivative which is shown here to have a 60-fold higher affinity for TS. The IC50 for inhibition of L1210 cell growth is below the Ki value of ICI D1694 for L1210 TS but above that of the tetraglutamate. The formation of polyglutamates and concentration of drug inside cells, therefore, seem to be responsible for biological activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596289     DOI: 10.1016/0006-2952(92)90646-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.

Authors:  L Jiang; P C Lee; J White; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 2.  Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  N S Gunasekara; D Faulds
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

3.  Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694.

Authors:  M Hekmat-Nejad; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase.

Authors:  Cullen K T Pang; Joshua H Hunter; Ramesh Gujjar; Ramulu Podutoori; Julie Bowman; Devaraja G Mudeppa; Pradipsinh K Rathod
Journal:  Mol Biochem Parasitol       Date:  2009-07-08       Impact factor: 1.759

5.  Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Authors:  L G Mendelsohn; C Shih; R M Schultz; J F Worzalla
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 6.  Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Authors:  A L Jackman; F T Boyle; K R Harrap
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.

Authors:  Michelle de Paula Reis; Daniely Alves de Lima; Karoline Bach Pauli; Carlos Eduardo Linhares Andreotti; André Luiz Soares de Moraes; Daniela Dib Gonçalves; Italmar Teodorico Navarro; Paulo Sérgio Alves Bueno; Flavio Augusto Vicente Seixas; Arquimedes Gasparotto Junior; Emerson Luiz Botelho Lourenço
Journal:  Parasitol Res       Date:  2018-03-17       Impact factor: 2.289

8.  Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase.

Authors:  P K Rathod; S Reshmi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 10.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.